Drug Trial Radar · NCT05266430
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Apr 14, 2022
Primary completion
Feb 1, 2023
Study completion Apr 20, 2023
Sponsor
- Lead sponsor
- Aura BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.
Conditions
- Choroidal Melanoma
- Indeterminate Lesions
Interventions
Standard of CareOther
Patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the investigator
AU-011Drug
Previously received
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual AcuityTime frame: 5 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Associated Retinal Consultants, P.C.
Royal Oak, Michigan
Oregon Health & Science University Casey Eye Institute
Portland, Oregon
Retina Consultants of Carolina, PA
Greenville, South Carolina
St. Thomas Health/Tennessee Retina, P.C.
Nashville, Tennessee
Retina Consultants of Texas
Bellaire, Texas
Texas Retina Associates
Dallas, Texas
University of Wisconsin Dept of Ophthalmology & Visual Sciences
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.